Effect of a delta receptor agonist on duration of survival during hemorrhagic shock

Richard L Summers1, Zizhuang Li, Drew Hildebrandt

  • 1Department of Emergency Medicine, University of Mississippi Medical Center, Jackson 39216, USA. rsummers@pol.net

Abstract

Insights

DADLE (D-Ala2-Leu5-enkephalin), a delta receptor agonist, significantly improved survival and hemodynamic stability in rats experiencing severe hemorrhagic shock. This study suggests DADLE may offer a novel therapeutic approach for shock resuscitation.

Area of Science:

  • Pharmacology
  • Physiology
  • Critical Care Medicine

Background:

  • Selective delta receptor agonists stabilize physiological processes and protect against ischemia via K(ATP) channel opening.
  • The impact of delta receptor agonists on generalized ischemia, such as hemorrhagic shock, remains unexplored.

Purpose of the Study:

  • To investigate the effects of the nonselective delta receptor agonist DADLE (D-Ala2-Leu5-enkephalin) on hemodynamic stability and survival in a rat model of severe hemorrhagic shock.

Main Methods:

  • Conscious Sprague Dawley rats received DADLE or a control treatment before undergoing induced hemorrhagic shock.
  • Hemodynamic parameters (mean arterial pressure, heart rate) and survival were monitored for three hours post-hemorrhage.

Main Results:

  • Hemorrhage induced similar initial hemodynamic shock in both groups.
  • DADLE treatment resulted in statistically significant improved survival (50% at 3.5 hours) compared to controls (0%).
  • Hemodynamic parameters stabilized in the DADLE group, while controls showed progressive deterioration.

Conclusions:

  • DADLE administration improved hemodynamic stability and prolonged survival in a severe hemorrhagic shock model.
  • Physiological manipulation with DADLE shows potential for improving shock resuscitation outcomes.
  • DADLE's coordinated actions may offer a novel therapeutic strategy for clinical shock management.

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship01:14

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...